Skip to Content

American Funds Fundamental Invs R3 RFNCX

Medalist Rating as of | See American Funds Investment Hub
  • NAV / 1-Day Return 81.55  /  −0.24 %
  • Total Assets 137.8 Bil
  • Adj. Expense Ratio
  • Expense Ratio 0.930%
  • Distribution Fee Level Low
  • Share Class Type Retirement, Medium
  • Category Large Blend
  • Investment Style Large Growth
  • Min. Initial Investment 250
  • Status Open
  • TTM Yield 0.74%
  • Turnover 28%

USD | NAV as of Jun 20, 2024 | 1-Day Return as of Jun 20, 2024, 10:18 PM GMT+0

Morningstar’s Analysis RFNCX

Will RFNCX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

A Swap at the Top Doesn’t Affect American Funds Fundamental Investors’ Ratings

null Stephen Welch

Stephen Welch

Analyst Note

Capital Group has announced that Brady Enright stepped down as lead principal investment officer of American Funds Fundamental Investors on April 1. Mark Casey, who has overseen the contributions of a team from Capital International Investors to this strategy since July 2018, will take Enright’s place allocating capital to the managers’ independently run portions of the portfolio. Enright will remain a manager on the strategy. Given Enright’s continued involvement and Casey’s readiness for the lead PIO role, the changes affect neither the strategy’s Above Average People and Process ratings nor its share classes’ respective Morningstar Medalist Ratings.

Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings RFNCX

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 29.4
Top 10 Holdings
% Portfolio Weight
Market Value USD

Broadcom Inc

6.40 8.8 Bil

Microsoft Corp

6.26 8.6 Bil

Meta Platforms Inc Class A

2.63 3.6 Bil
Communication Services

Alphabet Inc Class C

2.51 3.4 Bil
Communication Services

Capital Group Central Cash Fund

2.34 3.2 Bil
Cash and Equivalents

TransDigm Group Inc

2.34 3.2 Bil

Philip Morris International Inc

2.25 3.1 Bil
Consumer Defensive Inc

1.99 2.7 Bil
Consumer Cyclical

Novo Nordisk A/S Class B

1.83 2.5 Bil

UnitedHealth Group Inc

1.74 2.4 Bil